Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.05 +2.0%	$1.99	$1.60 ▼ $2.54	$775.22M	1.03	1.36 million shs	1.07 million shs
NUVB Nuvation Bio	$2.25 +0.8%	$2.14	$1.54 ▼ $3.97	$758.79M	1.33	3.11 million shs	3.24 million shs
REPL Replimune Group	$12.50 -1.0%	$9.44	$6.44 ▼ $17.00	$973.61M	0.61	935,837 shs	2.96 million shs
TVGN Semper Paratus Acquisition	$1.24 +0.8%	$1.23	$0.26 ▼ $3.09	$226.19M	-0.73	5.07 million shs	596,386 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+1.99%	-2.38%	+7.33%	+15.82%	-16.33%
NUVB Nuvation Bio	+0.09%	-2.94%	+30.26%	+14.35%	-33.72%
REPL Replimune Group	-1.03%	+16.06%	+31.44%	+56.45%	+17.59%
TVGN Semper Paratus Acquisition	+0.81%	+1.64%	+1.64%	+26.58%	+69.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.8611 of 5 stars	0.0	4.0	0.0	2.2	0.0	2.5
NUVB Nuvation Bio	3.1707 of 5 stars	4.6	0.0	0.0	2.4	4.2	0.0
REPL Replimune Group	4.1541 of 5 stars	3.6	1.0	4.5	2.5	2.5	0.6
TVGN Semper Paratus Acquisition	3.9849 of 5 stars	3.5	5.0	0.0	1.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
NUVB Nuvation Bio	3.20	Buy	$7.17	218.94% Upside
REPL Replimune Group	3.13	Buy	$21.00	68.00% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$10.00	706.45% Upside

Current Analyst Ratings Breakdown

Latest TVGN, REPL, NUVB, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$16.00 ➝ $19.00
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.72	$0.00 per share	4,319.61	$2.90 per share	0.71
NUVB Nuvation Bio	$7.87M	97.15	N/A	N/A	$1.37 per share	1.64
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	15.77	68.33	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)

Latest TVGN, REPL, NUVB, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRON Cronos Group	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q1 2026	REPL Replimune Group	-$0.85	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
NUVB Nuvation Bio	N/A	9.01	9.01
REPL Replimune Group	0.17	7.95	7.95
TVGN Semper Paratus Acquisition	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
NUVB Nuvation Bio	61.67%
REPL Replimune Group	92.53%
TVGN Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
NUVB Nuvation Bio	29.93%
REPL Replimune Group	8.80%
TVGN Semper Paratus Acquisition	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	357.53 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A

TVGN, REPL, NUVB, and CRON Headlines

Recent News About These Companies

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

July 17 at 9:15 AM | globenewswire.com

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

July 16 at 11:57 AM | globenewswire.com

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

July 14, 2025 | globenewswire.com

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

July 10, 2025 | globenewswire.com

Tevogen Bio Holdings Inc News (TVGN) - Investing.com

July 8, 2025 | investing.com

Semper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's Why

July 2, 2025 | marketbeat.com

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

June 30, 2025 | globenewswire.com

Semper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

June 18, 2025 | marketbeat.com

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

June 18, 2025 | globenewswire.com

Tevogen Bio

June 17, 2025 | thepharmaletter.comT

Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives

June 12, 2025 | nasdaq.com

Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft

June 10, 2025 | nasdaq.com

Tevogen Bio doubles Warren HQ footprint for AI expansion

June 10, 2025 | njbiz.comN

Ambitious Tevogen makes expansion announcement

June 10, 2025 | thepharmaletter.comT

Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

June 10, 2025 | insidertrades.com

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

June 9, 2025 | globenewswire.com

tevogen bio expands office lease in new jersey with key amendment

June 5, 2025 | investing.com

Tevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijziging

June 4, 2025 | nl.investing.com

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1, 2025 | nl.investing.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30, 2025 | quiverquant.comQ

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?

TVGN, REPL, NUVB, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$2.05 +0.04 (+1.99%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$2.03 -0.02 (-0.98%)

As of 07/17/2025 07:57 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Nuvation Bio NYSE:NUVB

$2.25 +0.02 (+0.76%)

Closing price 07/17/2025 03:59 PM Eastern

Extended Trading

$2.23 -0.02 (-0.76%)

As of 07/17/2025 07:58 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Replimune Group NASDAQ:REPL

$12.50 -0.13 (-1.03%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$12.56 +0.05 (+0.44%)

As of 07/17/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Semper Paratus Acquisition NASDAQ:TVGN

$1.24 +0.01 (+0.81%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.48%)

As of 07/17/2025 06:52 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time